Erdera selects two projects from the University of Padua
18.12.2025
Two projects from the University of Padua have been selected as part of the transnational Erdera (European Rare Diseases Research Alliance) call for proposals and funded by the Telethon Foundation. These include Tania Zaglia's study on arrhythmogenic cardiomyopathy and Stefano Comai's research on Fragile X syndrome and Phelan-McDermid syndrome.
The TREATYNG project, coordinated by Tania Zaglia (Department of Biomedical Sciences), investigates arrhythmogenic cardiomyopathy as a multicellular disease and evaluates neuropeptide-Y as a potential therapeutic target to slow disease progression, also developing new prognostic biomarkers.
The MT2ASD project, led by Stefano Comai (Department of Pharmaceutical Sciences), focuses on evaluating selective agonist drugs for the MT2 melatonin receptor as a new therapeutic approach for Fragile X syndrome and Phelan-McDermid syndrome, with the aim of preparing future clinical studies.
The projects selected by Erdera cover numerous rare and severe diseases and aim to produce solid preclinical evidence for the development of safer and more effective therapies. In the 2025 edition of the call, 18 transnational projects were funded out of 161 initial proposals, with a total budget of approximately 29 million euros, supported by 29 funding bodies from 23 countries and co-financed by the European Commission.
For Italy, participants included, among others, the Telethon Foundation, the Ministry of Health, and the Ministry of University and Research.
